Autologous stem cell transplantation

There are two primary types of hematopoietic stem cell transplantation: An autologous stem cell transplantation, and an allogeneic stem cell transplantation. The difference between the two types is simple: the terms allogeneic and autologous merely refer to the source of the stem cells: autologous stem cells come from the patient, and they are harvested in advance of the procedure. Allogeneic stem cells are harvested from a matched donor.

Autologous stem cell transplantation

.
When oncologists recommend an autologous stem cell transplantation for lymphoma patients, it is typically the last line of therapeutic defense against an otherwise refractory cancer. The idea behind this complicated procedure is rather simple: doctors remove healthy blood stem cells from the patient's body and freeze them so that they can then submit the patient to levels of chemotherapy and radiation high enough to kill the cancerous cells present in the body without affecting their stem cells. Afterwards, those stem cells are returned to the body, where they can develop into the various blood cells required for normal function, including the crucial lymphocytes. In doing so, they rebuild the patient's immune system.

The success of the procedure depends upon the efficacy of the radiation and the chemotherapy regimen in freeing the body of all remaining traces of cancer.

Because the patient is briefly without an active immune system, and because it takes time for the stem cells to rebuild the immune system, the patient is at risk of a wide range of opportunistic infections. During this time, it's not uncommon for old viral infections, such as Herpes or the Chicken Pox, to be re-activated because they are not being kept in check by the immune system. Fortunately, doctors can prepare for such events and mitigate their impact.

Sources

UpToDate.com, HSCT Patient Information

The National Marrow Donor Program

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap